Cargando…

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council

BACKGROUND: The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome measure designed to assess psoriasis signs and symptoms. OBJECTIVES: The aim was to assess the usefulness of the PSI in enhancing patient care in the clinical setting. METHODS: Eight dermatology clinics in six countries...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strober, Bruce, van de Kerkhof, Peter C. M., Callis Duffin, Kristina, Poulin, Yves, Warren, Richard B., de la Cruz, Claudia, van der Walt, Joelle M., Stolshek, Bradley S., Martin, Mona L., de Carvalho, Andre V. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764927/ https://www.ncbi.nlm.nih.gov/pubmed/31228013 http://dx.doi.org/10.1007/s40257-019-00458-2

Ejemplares similares

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council
por: Cohen, Arnon D., et al.
Publicado: (2020)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
por: Brummer, Grace C., et al.
Publicado: (2017)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Psoriasis and Atopic Dermatitis
por: Griffiths, Christopher E. M., et al.
Publicado: (2017)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA
por: Walsh, Jessica A, et al.
Publicado: (2018)

Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk
por: KLEYN, C. Elise, et al.
Publicado: (2020)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

The 5q31 variants associated with psoriasis and Crohn's disease are distinct
por: Li, Yonghong, et al.
Publicado: (2008)

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
por: Warren, R.B., et al.
Publicado: (2019)

Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis
por: Schwartz, Julia, et al.
Publicado: (2016)

Clinical Goals and Barriers to Effective Psoriasis Care
por: Strober, Bruce E., et al.
Publicado: (2018)

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities
por: Bronckers, I. M. G. J., et al.
Publicado: (2015)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Safety of treatment with biologics for psoriasis in daily practice: 5-year data
por: Van Lümig, PPM, et al.
Publicado: (2010)

Development of clinical diagnostic criteria for plaque psoriasis in children: an electronic Delphi consensus study with the International Psoriasis Council
por: Burden‐Teh, E., et al.
Publicado: (2019)

Multiple Loci within the Major Histocompatibility Complex Confer Risk of Psoriasis
por: Feng, Bing-Jian, et al.
Publicado: (2009)

Community differentiation of the cutaneous microbiota in psoriasis
por: Alekseyenko, Alexander V, et al.
Publicado: (2013)

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
por: PUIG, Lluís, et al.
Publicado: (2020)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
por: van de Kerkhof, P.C.M., et al.
Publicado: (2015)

A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain
por: Puig, L., et al.
Publicado: (2017)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis
por: Langewouters, A. M. G., et al.
Publicado: (2007)

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018)

Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report
por: Babalola, Olubukola, et al.
Publicado: (2014)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Microbiomic Signatures of Psoriasis: Feasibility and Methodology Comparison
por: Statnikov, Alexander, et al.
Publicado: (2013)

Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis
por: Sarma, Nilendu
Publicado: (2017)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
por: Mease, P.J., et al.
Publicado: (2019)

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
por: Gordon, KB, et al.
Publicado: (2014)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups
por: VAN WINDEN, Marieke E. C., et al.
Publicado: (2020)

The global state of psoriasis disease epidemiology: a workshop report
por: Griffiths, C.E.M., et al.
Publicado: (2017)

Disease Assessment in Psoriasis
por: Manchanda, Yashpal, et al.
Publicado: (2023)

Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy
por: Poulin, Yves, et al.
Publicado: (2014)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

Topical Therapy in Psoriasis
por: Ahmed, SK Shahriar, et al.
Publicado: (2023)

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
por: Gooderham, M., et al.
Publicado: (2022)

Psoriasis: classical and emerging comorbidities()
por: de Oliveira, Maria de Fátima Santos Paim, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jf8rnsrj2vpfq96a93f255memd